Contamination Assessment for Cancer Next-Generation Sequencing Method Development and Clinical Implementation

1Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Context.—The presence of allogeneic contamination impacts clinical reporting in cancer next-generation sequencing specimens. Although consensus guidelines recommend the identification of contaminating DNA as a part of quality control, implementation of contamination assessment methods in clinical molecular diagnostic laboratories has not been reported in the literature. Objective.—To develop and implement a method to assess allogeneic contamination in clinical cancer next-generation sequencing specimens. Design.—We describe a method to detect contamination based on the evaluation of single-nucleotide polymorphic sites from tumor-only specimens. We validate this method and apply it to a large cohort of cancer sequencing specimens. Results.—Identification of specimen contamination was validated via in silico and in vitro mixtures, and reference range and reproducibility were established in a panel of normal specimens. The algorithm accurately detects an episode of systemic contamination due to reagent impurity. We prospectively applied this algorithm across 7571 clinical cancer specimens from a targeted next-generation sequencing panel, in which 262 specimens (3.5%) were predicted to be affected by greater than 5% contamination. Conclusions.—Allogeneic contamination can be inferred from intrinsic cancer next-generation sequencing data without paired normal sequencing. The adoption of this approach can be useful as a quality control measure for laboratories performing clinical next-generation sequencing.

References Powered by Scopus

Cancer genome landscapes

6054Citations
N/AReaders
Get full text

DbSNP: The NCBI database of genetic variation

5623Citations
N/AReaders
Get full text

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

3598Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations

18Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Li, Y. Y., Schmidt, R. J., Manning, D. K., Jia, Y., & Dong, F. (2022). Contamination Assessment for Cancer Next-Generation Sequencing Method Development and Clinical Implementation. Archives of Pathology and Laboratory Medicine, 146(2), 227–232. https://doi.org/10.5858/ARPA.2020-0679-OA

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

50%

Researcher 2

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

43%

Nursing and Health Professions 2

29%

Agricultural and Biological Sciences 1

14%

Neuroscience 1

14%

Save time finding and organizing research with Mendeley

Sign up for free